Evotec AG, the Hamburg-based drug development company focused on treatments for the central nervous system, announced that Flemming Ornskov will be nominated chairman of the supervisory board at its forthcoming annual general meeting, replacing Heinz Riesenhuber, who will become honorary chairman.
Dr Ornskov is currently a vice president at Bausch & Lomb, the US eye care company. Previously, he was CEO and president of LifeCycle Pharma, an emerging cardiovascular company. Before that, he served as CEO and president of biotech start-up Ikaria, Inc. From 2002 to 2005, he was president of the ophthalmics business unit for Novartis, and formerly led Novartis' US cardiovascular franchise. Dr. Ornskov has also held multiple leadership positions at Merck & Co.
Dr. Ornskov received a MD degree from University of Copenhagen, a MBA degree from INSEAD and a Master of Public Health degree from Harvard University.
Source
Evotec press release, 21 July 2008
Copyright 2008 Evernow Publishing Ltd